Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Equity (2016 - 2025)

China Pharma Holdings' Return on Equity history spans 15 years, with the latest figure at 0.21% for Q4 2025.

  • For Q4 2025, Return on Equity rose 46.0% year-over-year to 0.21%; the TTM value through Dec 2025 reached 0.21%, up 46.0%, while the annual FY2025 figure was 0.21%, 41.0% up from the prior year.
  • Return on Equity reached 0.21% in Q4 2025 per CPHI's latest filing, up from 0.43% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.21% in Q4 2025 to a low of 1.12% in Q4 2022.
  • Average Return on Equity over 5 years is 0.62%, with a median of 0.58% recorded in 2023.
  • Peak YoY movement for Return on Equity: soared 199bps in 2021, then plummeted -59bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.53% in 2021, then plummeted by -111bps to 1.12% in 2022, then soared by 59bps to 0.45% in 2023, then tumbled by -46bps to 0.66% in 2024, then surged by 69bps to 0.21% in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Return on Equity are 0.21% (Q4 2025), 0.43% (Q3 2025), and 0.54% (Q2 2025).